SAP v Versata decision threatens business method patents

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

SAP v Versata decision threatens business method patents

uspto-seal-45.gif

Business method patent owners were dealt a blow this week after the PTAB confirmed it will assume the “broadest reasonable interpretation” of a patent when considering if its claims are too far-reaching under new post-grant challenge proceedings

In the first-ever covered business method (CBM) review trial, the USPTO’s Patent Trial and Appeal Board (PTAB) found all five challenged claims in SAP v Versata invalid.

uspto-seal-200.gif

The PTAB concluded that Versata’s claims relating to a method and apparatus for pricing products and services are ineligible for patent protection under Section 101. Versata’s system arranges customers and products into a hierarchy and applies pricing adjustments to different groups.

The CBM review trial is a new post-grant patent challenge proceeding created under the AIA. Designed to reduce the number of overly broad business method patents, it allows those accused of infringing a patent covered under Section 18 of the AIA to challenge its validity through the USPTO’s appeals procedure rather than through the court system.

CBM review was introduced in September 2012. The USPTO will not accept any new petitions for CMB review on or after September 16, 2020.

Versata had argued that the terms for judging the validity of the claims should be based on a district court interpretation standard. But Administrative Patent Judges Sally Medley, Michael Tierney and Rama Elluru disagreed.

“The use of the broadest reasonable interpretation encourages patent owners to remove ambiguities and to narrow their claims by amendment, such that the inventor’s contribution to the art is expressed in clear, precise and unambiguous terms,” they said.

The dispute began in 2007, when Versata sued for infringement of US patent 6,553,350. A district court jury found that SAP had infringed the patent and awarded damages.

Both parties appealed to the Federal Circuit in October 2011. The appellate court affirmed the jury’s verdict and damages.

In September 2012, SAP filed a petition with the USPTO challenging claims 17 and 26 to 29 as being ineligible for patent protection. Versata claimed that SAP had failed to meet all three criteria for seeking a CBM review, but in February this year the PTAB disagreed and ordered that the review should go ahead.

more from across site and SHARED ros bottom lb

More from across our site

Erise IP has added a seven-practitioner trademark team from Hovey Williams, signalling its intention to help clients at all stages of development
News of prison sentences for ex-Samsung executives for trade secrets violation and an opposition filed by Taylor Swift were also among the top talking points
A multijurisdictional claim filed by InterDigital and a new spin-off firm in Germany were also among the top talking points
Duarte Lima, MD of Spruson & Ferguson’s Asia practice, says practitioners must adapt to process changes within IP systems, as well as be mindful of the implications of tech on their practices
Practitioners say the UK Supreme Court’s decision could boost the attractiveness of the UK for AI companies
New awards, including US ‘Firm of the Year’ and Latin America ‘Firm to Watch’, are among more than 90 prizes that will recognise firms and practitioners
DWF helped client Dairy UK secure a major victory at the UK Supreme Court
Hepworth Browne led Emotional Perception AI to victory at the UK Supreme Court, which rejected a previous appellate decision that said an AI network was not patentable
James Hill, general counsel at Norwich City FC, reveals how he balances fan engagement with brand enforcement, and when he calls on IP firms for advice
In the second of a two-part article, Gabrielle Faure-André and Stéphanie Garçon at Santarelli unpick EPO, UPC and French case law to assess the importance of clinical development timelines in inventive step analyses
Gift this article